Recent data indicates a deceleration in vehicle delivery rates. Tesla reported deliveries exceeding 418,000 units in the fourth quarter, representing a 16% year-over-year decrease. Full-year deliveries reached 1.64 million, a decline of nearly 9% from the preceding year. These figures, while substantial in absolute terms, warrant careful consideration given the increasingly competitive landscape.
At the Consumer Electronics Show, they unveiled Panther Lake. A family of CPUs, you understand. Not a dynasty, not yet. But the first to be born from the Intel 18A process. A process, they claim, that represents a ‘significant leap.’ One imagines the engineers, pale and exhausted, whispering incantations over silicon wafers. Early reports are… encouraging. PCWorld, a publication not known for its excessive modesty, declared, and I quote, “Intel doesn’t suck anymore.” A statement of such profound simplicity, it borders on philosophy. Panther Lake promises battery life, performance, even a foray into the realm of handheld gaming. A bold move, considering Intel’s recent tendency towards… caution. Nova Lake follows, a more ambitious undertaking. And then there’s Serpent Lake, a whispered rumor of collaboration with Nvidia. A pact with the… well, never mind. It may prove a chimera, but one can dream. The question isn’t whether Intel can build chips, but whether they have the courage to truly innovate.
Following a period of, shall we say, excessive enthusiasm in 2024 – a surge of approximately 1,710% – Quantum Computing encountered a recalibration. This recalibration, predictably, proved to be asymmetrical, a downward correction disproportionate to any discernible change in fundamental reality. It registered as the weakest performance amongst its cohort of quantum-focused entities.
While the broader market – that vast, chaotic bazaar known as the S&P 500 and its more excitable cousin, the Nasdaq Composite – enjoyed a respectable climb, Rocket Lab distinguished itself. It wasn’t merely carried by the tide, oh no. It appears to have sprouted wings, or perhaps a particularly efficient series of combustion chambers. This ascent coincided, naturally, with impressive sales – though what constitutes ‘impressive’ when one is selling access to the heavens is a question for theologians and accountants – and a flurry of agreements. And then, of course, there is the matter of SpaceX. That behemoth, poised to enter the public market, casting a long, shimmering shadow over all who dare to dream of escaping Earth’s gravity.
Both are managed by the same house of Invesco, yet their philosophies diverge sharply. QQQ, a devotee of the grand and glittering, concentrates its affections upon the largest companies listed on the Nasdaq, with a particular fondness for those engaged in the art of technology. RSP, by contrast, affects a democratic spirit, distributing its patronage equally amongst all 500 members of the S&P 500. A most peculiar arrangement, wouldn’t you agree?
AbbVie’s got a whole stable of medicines, treatin’ everything under the sun. But two in particular are pullin’ most of the weight: Skyrizi and Rinvoq. They’re addressin’ a heap of ailments – eczema, arthritis, the lot. Seems these two have surprised even the folks runnin’ the company, and that’s sayin’ somethin’.
The question, naturally, is whether acquiring shares in Robinhood at this particular moment in spacetime might, shall we say, set you up for life. A rather grand ambition, isn’t it? (One imagines a life consisting entirely of exotic fruit, perfectly brewed tea, and a complete avoidance of user agreements.) It’s a tempting proposition, but one requiring a degree of scrutiny that extends beyond a cursory glance at the share price. I suspect the answer, as is so often the case with financial matters, is…complicated.
I’m putting it out there: a new all-time high for XRP this year, ending above $4. Bold? Maybe. Stupid? Possibly. But I’ve stared into the abyss of crypto charts for far too long to ignore the occasional flicker of… something. It’s a long shot, absolutely, but then again, aren’t all the best investments? The ones that keep you up at night, questioning your life choices?
The market always has its darlings. Last year, it seemed Lumen had caught a fleeting glance from the fickle goddess of speculation. New deals, whispers about AI… it was a cocktail of hope and hype. The kind that usually leaves a bad taste, but this time, it lingered.
It appears that, much to the chagrin of those with grand expectations, the larger-cap altcoins exhibit a similar sluggishness, save for the modest blossoms of HYPE and TRX which, like overzealous garden blooms, have managed to sprout forth. In stark contrast, XMR continues its rather dramatic descent after achieving a mid-week zenith, akin to a tragic hero meeting an untimely end.